Identifying novel pathways at the interface of immunity and metabolism

Discovery Platform

Landos’ AI-based integrated computational discovery platform has produced a pipeline of potentially first-in-class oral small molecule therapeutic candidates with differentiated profiles designed to address autoimmune, inflammatory, metabolic, and other diseases. This platform has enabled Landos to identify and advance four novel molecules across eight indications in two mechanistic libraries that have the potential to restore the immune tolerance for patients with autoimmune disease.

Over 10,000 Potential Target

Section 1
Omics patient data from multiple sources: Responders vs. non-responders, active disease vs. remission
Input
Identify blind spots and linkages in immunometabolic pathways
80-100
TARGET PATHWAYS
In Silico
Use AI-based filter for druggability
Conduct multi-scale pathway modeling
(ODE & ABM)
5-10
TARGET PATHWAYS
In Silico
Leverage CRISPR, siRNA, shRNA experimental results with primary human and other cells
2-3
TARGET PATHWAYS
In Vivo
Characterize phenotype of knock-out mice and investigate effects in multiple animal models IBD, SLE MS, T1D

Foundational Pillars:

  • Target well-conserved and stable immunometabolic processes that could prove a successful strategy for therapeutic efficacy
  • Prioritize patient safety
  • Design targets to restore immune tolerance that may drive more durable clinical response and remission
  • Identify novel pathways with promising potential to innovate the treatment of autoimmune disease